Aktie A3C8W7 NUVECTIS PHARMA, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Nuvectis Pharma, Inc.

Aktien

A3C8W7

US67080T1088

NVCT

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 20:17:43 22.05.2024 		% 5 Tage % 1. Jan.
6,32 USD +3,95 % Intraday Chart für Nuvectis Pharma, Inc. -6,32 % -25,30 %
07.05. Nuvectis Pharma, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
08.04. Nxp900 von Nuvectis Pharma zeigt robuste Aktivität bei nicht-kleinzelligen Lungenkrebs-Zelllinien CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Nuvectis Pharma to Present at the 36th Annual Roth Conference
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3C8W7 Aktie
  4. Nachrichten Nuvectis Pharma, Inc.
  5. Andere Sprachen